Investor Relations

Company Overview

Humanigen, Inc. is a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments. Derived from the company's Humaneered® platform, lenzilumab, ifabotuzumab and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential medicine to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets Eph receptor A3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a backbone for a novel CAR-T construct and bispecific antibody platform. HGEN005, which targets human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1), has potential as a treatment for eosinophilic diseases, such as a novel CAR-T construct for eosinophilic leukemia.

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Latest 10-K

For Fiscal Year 2017

Download 10-K

Stock Information

Symbol

OTCQB: HGEN

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations

Al Palombo
T: 650-243-3181
ir@humanigen.com

Transfer Agent

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
T: 800-662-7232
www.computershare.com